AdaptHealth Corp

AdaptHealth Corp. engages in the provision of home healthcare equipment, supplies and related services. It focuses on sleep therapy equipment to individuals suffering from obstructive sleep apnea (OSA), home medical equipment to patients discharged from acute care and other facilities, oxygen and related chronic therapy services in the home, and HME medical devices and supplies on behalf of chronically ill patients with diabetes care, wound care, urological, ostomy, and nutritional supply needs. The company was founded in 2012 and is headquartered in Plymouth Meeting, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AdaptHealth Corp reports robust revenue growth and strategic investments outlook

AdaptHealth Corp demonstrated resilience in revenue growth despite challenges, with a strong focus on patient care and financial performance. While facing short-term obstacles, the company is strategically positioned to capitalize on growth opportunities and improve margins through cost-cutting measures.

AdaptHealth Corp reports revenue growth amidst diabetes business challenges

AdaptHealth Corp's Q1 2023 performance showed revenue growth but faced challenges in the diabetes business, prompting cost-saving measures.
Despite hurdles, the company remains confident in its strategy, focusing on growth opportunities and operational efficiency to drive performance.
Management's proactive approach to cost reduction and revenue enhancement positions AdaptHealth well for future growth and financial stability.

AdaptHealth Corp posts solid Q2 results, eyes growth opportunities

AdaptHealth Corp's Q2 performance reflects strong revenue growth and improved EBITDA, driven by key product lines.
While challenges exist in the diabetes segment, the company is focused on operational enhancements and cost-saving measures.
Opportunities for growth and efficiency improvements are present, with a commitment to executing strategies and leveraging expertise.
Management's emphasis on financial processes and operational efficiency bodes well for future performance and market positioning.

AdaptHealth Corp reports record revenues, faces EBITDA challenges, eyes growth

AdaptHealth Corp's Q3 performance reflects revenue growth driven by the sleep business, with a focus on enhancing patient experience. Challenges include EBITDA shortfall due to contract delays and impairment to goodwill. The company is seizing opportunities in CGM data utilization and diversification strategies for growth.
With a strong emphasis on patient care and operational efficiency, AdaptHealth Corp is navigating challenges in revenue decline and tough comps, aiming for sustained growth. The company's strategic focus on market penetration and patient outcomes positions them for future success.

AdaptHealth Corp excels in Q4 2023, eyes growth opportunities

AdaptHealth Corp's strong performance in Q4 2023 and full-year highlights organic growth.
Challenges from GLP-1 drugs and government exposure are being addressed proactively.
Opportunities lie in projected revenue growth, market share improvement, and cost reduction.
Overall, AdaptHealth is well-positioned for continued growth and market resilience.

AdaptHealth Corp excels in Q1 2024, eyes growth and debt reduction

AdaptHealth Corp's Q1 2024 performance reflects solid financial growth, operational improvements, and strategic initiatives aimed at enhancing profitability and market position.
While challenges like managing potential risks in key segments and addressing debt obligations exist, the company's strengths in leadership, revenue diversification, and cost management provide a strong foundation for future success.
By capitalizing on growth opportunities in key business segments and markets, AdaptHealth Corp is well-positioned to achieve its financial targets, drive sustainable growth, and enhance shareholder value.

AdaptHealth Corp reports solid Q2 results and raises full-year guidance

AdaptHealth Corp's Q2 performance met expectations with a strong focus on driving growth through investments and operational improvements. Despite challenges in certain revenue segments, the company remains optimistic about future prospects.

AdaptHealth Corp reports solid Q3 performance amid operational enhancements

AdaptHealth Corp's Q3 results reflect resilience and strategic initiatives to drive growth amidst operational challenges.
The company's proactive measures to address issues in the diabetes segment and optimize other product lines position it for future success.
With a strengthened financial position and a focus on operational efficiency, AdaptHealth is poised for sustainable growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW YORK, NY / ACCESSWIRE / July 9, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against AdaptHealth Corp. f/k/a DFB Healthcare Acquisitions Corp. (NASDAQ: AHCO). The settlement provides for a fund of $52,000,000 to benefit class members.

Levi & Korsinsky, LLP Notifies Shareholders of AdaptHealth Corp. f/k/a DFB Healthcare Acquisitions Corp. (AHCO) on Upcoming Claims Deadline in a Class Action Settlement

Prestige Brands Holdings

Investors interested in stocks from the Medical - Products sector have probably already heard of AdaptHealth Corp. (AHCO) and Prestige Consumer Healthcare (PBH). But which of these two stocks is more attractive to value investors?

AHCO or PBH: Which Is the Better Value Stock Right Now?

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--AdaptHealth Corp. (NASDAQ: AHCO) (“AdaptHealth” or the “Company”), a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment, medical supplies, and related services, announced today the appointment of Dale Wolf as Chair of the Board of Directors, effective July 1, 2024. Mr. Wolf has served on AdaptHealth's Board since November 2019 and will assume the role from outgoing Chairman Richard Barasch. Additio.

AdaptHealth Corp. Announces Changes to Board of Directors and Management

NEW YORK, NY / ACCESSWIRE / July 2, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against AdaptHealth Corp. f/k/a DFB Healthcare Acquisitions Corp. (NASDAQ: AHCO). The settlement provides for a fund of $52,000,000 to benefit class members.

Deadline Approaching for Receiving Share of AdaptHealth Corp. f/k/a DFB Healthcare Acquisitions Corp. (AHCO) Recovery - Contact Levi & Korsinsky, LLP for Further Details

NEW YORK, NY / ACCESSWIRE / June 27, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against AdaptHealth Corp. (NASDAQ: AHCO). The settlement provides for a fund of $51,000,000 to benefit class members.

Levi & Korsinsky, LLP Notifies Shareholders of AdaptHealth Corp. (AHCO) on Upcoming Claims Deadline in a Class Action Settlement

NEW YORK, NY / ACCESSWIRE / June 25, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against AdaptHealth Corp. (NASDAQ:AHCO). The settlement provides for a fund of $51,000,000 to benefit class members.

AdaptHealth Corp. (AHCO) Shareholders - L&K, LLP Encourages you to File a Claim Against the Settlement Fund Before Deadline

NEW YORK, NY / ACCESSWIRE / June 20, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against AdaptHealth Corp. (NASDAQ:AHCO). The settlement provides for a fund of $51,000,000 to benefit class members.

Deadline Approaching for Receiving Share of AdaptHealth Corp. (AHCO) Recovery - Contact Levi & Korsinsky, LLP for Further Details

NEW YORK, NY / ACCESSWIRE / June 11, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against AdaptHealth Corp. (NASDAQ:AHCO). The settlement provides for a fund of $51,000,000 to benefit class members.

Levi & Korsinsky, LLP Announces $51,000,000 Recovery for AdaptHealth Corp. (AHCO). File Your Claim Before Deadline

Investors can contact the law firm at no cost to learn more about recovering their losses.

The Portnoy Law Firm Announces Investigation of AdaptHealth Corp. (NASDAQ: AHCO)

NEW YORK, NY / ACCESSWIRE / June 6, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against AdaptHealth Corp. (NASDAQ: AHCO). The settlement provides for a fund of $51,000,000 to benefit class members.

Time Sensitive - Reminder from Levi & Korsinsky, LLP to File Claim for Share of AdaptHealth Corp. (AHCO) Settlement Fund Before Deadline

NEW YORK, NY / ACCESSWIRE / May 30, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against AdaptHealth Corp. (NASDAQ: AHCO). The settlement provides for a fund of $51,000,000 to benefit class members.

Levi & Korsinsky, LLP Notifies Shareholders of AdaptHealth Corp. (AHCO) an Upcoming Claims Deadline in a Class Action Settlement

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--AdaptHealth Corp. (NASDAQ: AHCO) (“AdaptHealth” or the “Company”), a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment, medical supplies, and related services, announced today that they will participate in the Goldman Sachs 45th Annual Global Healthcare Conference, being held in Miami, on Wednesday, June 12, 2024, including a presentation at 9:20am ET. About AdaptHealth Corp. AdaptHealth is a nati.

AdaptHealth Corp. to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--AdaptHealth Corp. (NASDAQ: AHCO) (“AdaptHealth” or the “Company”), a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment, medical supplies, and related services, announced today that they will participate in the Jefferies Global Healthcare Conference, being held in New York, on Wednesday, June 5, 2024, including a fireside chat at 4:00pm ET. The webcast link will be available on the Company's websit.

AdaptHealth Corp. to Participate in the Jefferies Global Healthcare Conference

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--AdaptHealth Corp. (NASDAQ: AHCO) (“AdaptHealth” or the “Company”), a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment, medical supplies, and related services, announced today that they will participate in the UBS Healthcare Services Cape Cod Summit, being held on Tuesday, June 4, 2024. About AdaptHealth Corp. AdaptHealth is a national leader in providing patient-centered, healthcare-at-home solut.

AdaptHealth Corp. to Participate in the UBS Healthcare Services Cape Cod Summit

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--AdaptHealth Corp. (NASDAQ: AHCO) (“AdaptHealth” or the “Company”), a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment, medical supplies, and related services, announced today that AdaptHealth granted restricted stock units covering 553,251 shares of the Company's common stock at target performance levels (the “Inducement RSUs”) to Suzanne Foster, AdaptHealth's newly appointed Chief Executive Offi.

AdaptHealth Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--AdaptHealth Corp. (NASDAQ: AHCO) (“AdaptHealth” or the “Company”), a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment, medical supplies, and related services, announced today that they will participate in the Leerink Partners Healthcare Crossroads Conference, being held in Austin, on Wednesday, May 29, 2024, including a fireside chat at 3:00pm CT. The webcast link will be available on the Company.

AdaptHealth Corp. to Participate in the 2024 Leerink Partners Healthcare Crossroads Conference

Celestica

Teladoc

Finding investing opportunities in the market might be challenging. Nevertheless, three equities stick out due to their ability to yield large profits during volatility.

3 High-Potential Stocks to Buy at Rock-Bottom Prices

AdaptHealth came public in 2019 through a SPAC merger and has been in the penalty box as other SPACS crashed the past 2 years. Yet earnings are growing rapidly and revenues are also steadily growing. Earnings strength has been masked by non-recurring items related to mergers and goodwill write-offs and management not showing an adjusted EPS.

AdaptHealth Is Too Strong To Be Valued At 40% Of Revenues

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--AdaptHealth Corp. (NASDAQ: AHCO) (“AdaptHealth” or the “Company”), a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment, medical supplies, and related services, announced today that Richard Barasch, Chairman and interim CEO, and Jason Clemens, CFO, will participate in the BofA Securities 2024 Health Care Conference, being held in Las Vegas, on Wednesday, May 15, 2024, including a fireside chat at 4.

AdaptHealth Corp. to Participate in the BofA Securities 2024 Health Care Conference

AdaptHealth Corp. (AHCO) came out with quarterly earnings of $0.02 per share, missing the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.01 per share a year ago.

AdaptHealth Corp. (AHCO) Lags Q1 Earnings Estimates

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--AdaptHealth Corp. (NASDAQ: AHCO) (“AdaptHealth” or the “Company”), a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment, medical supplies, and related services, announced today financial results for the first quarter ended March 31, 2024. First Quarter Results and Highlights All comparisons are to the quarter ended March 31, 2023. Net revenue was $792.5 million compared to $744.6 million, an increa.

AdaptHealth Corp. Announces First Quarter 2024 Results

Boston Scientific

Investors with an interest in Medical - Products stocks have likely encountered both AdaptHealth Corp. (AHCO) and Boston Scientific (BSX). But which of these two stocks presents investors with the better value opportunity right now?

AHCO vs. BSX: Which Stock Is the Better Value Option?

Here is how AdaptHealth Corp. (AHCO) and Arcutis Biotherapeutics, Inc. (ARQT) have performed compared to their sector so far this year.

Is AdaptHealth (AHCO) Stock Outpacing Its Medical Peers This Year?

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--AdaptHealth Corp. (NASDAQ: AHCO) (“AdaptHealth” or the “Company”), a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment, medical supplies, and related services, will release its first quarter 2024 financial results before the opening of the financial markets on Tuesday, May 7, 2024. Management will host a teleconference at 8:30 a.m. ET to discuss the results and business activities with analysts an.

AdaptHealth Corp. Announces First Quarter 2024 Earnings Release Date and Conference Call

Eli Lilly

ResMed

One of the pharmaceutical giant's hotter medications tested well for a new indication. It has already attracted much attention for the molecule being studied, as it's used in two FDA-approved treatments already.

News for AdaptHealth Corp Stock (AHCO)